Karyopharm Therapeutics
Jeanne Matey is a seasoned professional in hematology and oncology sales, currently serving as a Senior Hematology/Oncology Sales Specialist at Karyopharm Therapeutics Inc. since March 2021, where notable achievements include winning the President's Club in 2022 and successfully launching new indications for a first-in-class XPO1 inhibitor in multiple myeloma and diffuse large B-cell lymphoma. Previous experience includes roles as a Territory Manager at Clovis Oncology and Fortovia Therapeutics, where successful product launches and sales performance were achieved, as well as leading initiatives as an Oncology Sales Specialist. Early career experience includes entrepreneurial leadership at Soulful Art Studios and various sales roles, including management positions at Verizon Wireless, demonstrating a strong foundation in sales, strategic marketing, and account management. Jeanne holds a Bachelor's Degree in Communication Studies and Art from Mercer University.
This person is not in the org chart
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).